Brief: Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA Nephropathy
10/03/2025 11:43
March 10 (Reuters) - Arrowhead Pharmaceuticals Inc ARWR.O: ARROWHEAD PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FROM PART 2 OF PHASE 1/2 STUDY OF ARO-C3 IN PATIENTS WITH IGA NEPHROPATHY ARROWHEAD PHARMACEUTICALS INC - ARO-C3 GENERALLY WELL-TOLERATED IN PATIENTS WITH IGAN ARROWHEAD PHARMACEUTICALS INC - NO SERIOUS OR SEVERE TREATMENT EMERGENT ADVERSE EVENTS REPORTED Source text: nBw3yHhH8a Further company coverage: ARWR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers